Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

Andreas R. de Biasi1,2, Jonathan Villena-Vargas1,2, and Prasad S. Adusumilli1,2

Abstract

Contrary to the long held belief that chemotherapy is immunosuppressive, emerging evidence indicates that the anticancer activity of cisplatin is not limited to its ability to inhibit mitosis, but that cisplatin also has important immunomodulatory effects. We therefore methodically examined the relevant preclinical literature and identified four main mechanisms of cisplatin-induced antitumor immunomodulation: (i) MHC class I expression upregulation; (ii) recruitment and proliferation of effector cells; (iii) upregulation of the lytic activity of cytotoxic effectors; and (iv) downregulation of the immunosuppressive microenvironment. Cisplatin-based combination chemotherapy’s antitumor immunomodulatory effects are also beginning to be harnessed in the clinic; we therefore additionally reviewed the applicable clinical literature and discussed how monitoring various components of the immune system (and their responses to cisplatin) can add new levels of sophistication to disease monitoring and prognostication. In summation, this growing body of literature on cisplatin-induced antitumor immunomodulation ultimately highlights the therapeutic potential of synergistic strategies that combine traditional chemotherapy with immunotherapy.

Introduction

The history of cisplatin (CDDP) dates back more than 160 years. Cisplatin was first synthesized by Michel Peyrone in 1845; some 50 years later, it played a pivotal role in the establishment of Alfred Werner’s theory of coordination chemistry, for which he won a Nobel Prize in 1913 (1). Then, in the mid-1960s, University of Michigan (Ann Arbor, MI) biophysicist Barnett Rosenberg unexpectedly discovered that CDDP could inhibit cellular division in Escherichia coli (2–4). Subsequently, Rosenberg became interested in testing CDDP for anticancer activity; he would go on to demonstrate the molecule’s potent antitumor activity in a murine model of sarcoma (5, 6). Rosenberg’s promising results in mice paved the way for trials in humans and ultimately led to CDDP becoming one of the most widely used chemotherapeutic agents in clinical practice today.

The anticancer activity of CDDP is not merely limited to its ability to cross-link DNA and inhibit mitosis (these events, in turn, lead to apoptosis). Rather, we are now learning that CDDP also has immunomodulatory effects. These effects may be quite important for combating tumors and stand in stark contrast with the more well-known immuno- (killing of circulating lymphocytes) and myelosuppressive (bone marrow impairment) actions of most chemotherapies (including CDDP). What is more, our improved understanding of this CDDP-induced antitumor immunomodulation comes at a time when emerging antineoplastic strategies are increasingly engaging the immune system directly (e.g., check-point blockade and adoptive T-cell therapies). Interestingly, recent developments in oncology involve synergizing such novel immunotherapies with conventional chemotherapeutics such as doxorubicin and CDDP-based treatments. These combinations may have initially sought to exploit CDDP’s direct cytotoxic effects; but, as we are now learning, such combinations also serendipitously harness CDDP’s ability to favorably modulate the immune system. However, fully exploiting the potential benefits of these new CDDP-combined modalities first requires a thorough understanding of how CDDP itself interacts with the immune system. We therefore methodically examined both the current preclinical and clinical evidence addressing CDDP-mediated antitumor immunomodulation and herein summarize the relevant contemporary literature. In doing so, we identified four main mechanisms by which CDDP could modulate the immune system to further promote the drug’s antitumor efficacy: (i) CDDP upregulates MHC class I expression; (ii) CDDP promotes the recruitment and proliferation of effector cells; (iii) CDDP upregulates...
the lytic activity of cytotoxic effectors; and (iv) CDDP downregulates the immunosuppressive microenvironment (Fig. 1).

Although a recently published article in this journal examined the molecular pathways underlying the immunogenic effects of platinum-based chemotherapeutics, our
review focuses solely on CDDP and its interactions with the solid tumor microenvironment and the influence on outcomes (7).

Preclinical Evidence

CDDP upregulates MHC class I expression

The fundamental mechanism by which the immune system attempts to keep tumor cells at bay is through recognition of cancer cell’s MHC class I:peptide complex by a cytotoxic T-cell (CTL). When a CTL recognizes this complex via its T-cell receptor, it becomes activated and is able to perform its cytotoxic function against the tumor cell. It is now well established that many cancers attempt to avoid such immune recognition by downregulating their expression of MHC class I molecules (Fig. 1). A number of groups, however, have recently demonstrated that CDDP may improve the ability of CTLs to recognize cancer cells by upregulating the tumor cells’ MHC class I expression. Gameiro and colleagues showed that MHC class I expression increased more than 50% in the H1703 and A549 lung cancer cell lines after the cells were treated with a single, sublethal dose of CDDP/vinorelbine (8). A similar increase in MHC class I expression was observed with human head and neck squamous cell cancer (HNSCC) cell lines exposed to clinically translatable doses of CDDP plus 5-Fluorouracil (9).

It should be pointed out that the aforementioned studies used CDDP in translational settings and in combination with other standard agents (as do several other works cited in this review). Although the observed results cannot be fully attributed to CDDP’s actions alone, they nevertheless highlight the important immunologic impact such real-world, CDDP-based regimens may have. Still, a single, relatively low dose of CDDP has been demonstrated to elevate the expression of total cellular MHC class I in breast cancer ZR-75-1 cells (10); MHC class I expression was likewise increased with exposure of HPV-16 E7-expressing TC-1 murine tumor cells to CDDP in vitro (11).

Comparable results have been shown in vivo translating into improved antitumor efficacy. Using a murine model of plasmacytoma, Nio and colleagues subcutaneously inoculated cancer cells that were pretreated with either CDDP or an ethanol control (12). The potential to reject tumor was lower in mice injected with control tumor cells and flow cytometry demonstrated that the tumor cell expression of the MHC class I antigens, H-2Dd and H-2Kd, was enhanced with CDDP treatment (12). MHC class I expression in response to systemic CDDP treatment was demonstrated in a murine colorectal cancer model (13). Cisplatin administered at IC50 doses increased the expression of MHC class I molecules in two human colorectal cancer cell lines (COLO 201 and colon 26) in vitro; analogous MHC class I upregulation was observed on cancer cells harvested from colon-26-tumor-bearing mice treated with CDDP (13).

Interestingly, CDDP’s ability to upregulate MHC class I expression may not be limited to just tumor cells but, as Jackaman and colleagues illustrated, CDDP may also increase MHC class I expression on antigen-presenting cells (APC; ref. 14). In a murine mesothelioma-presentation model, the authors treated tumor-bearing mice with either two doses of CDDP or a PBS control and demonstrated that tumor-associated CD11c+ dendritic cells from mice treated with CDDP had greater MHC class I expression than did the dendritic cells from control mice (14).

Thus, accumulating evidence intriguingly suggests that even small, single doses of CDDP can be effective in upregulating MHC class I expression, both on tumor targets and on host APCs. Because the kinetics of this modulation are only on the order of several days, one can envision treatment scenarios in which a small “MHC-priming” dose of CDDP could be given before a complementary immunotherapy.

CDDP promotes recruitment and proliferation of effector cells

Although MHC class I expression is vital for CTL activation, the ability of the immune system to combat tumor is also dependent on the capacity of immune effector cells (including CTLs) to home to and accumulate within the tumor microenvironment. Mounting preclinical evidence now suggests that CDDP may promote the recruitment and subsequent proliferation of these effector cells (Fig. 1).

Chang and colleagues studied the immunomodulatory effects of a dose-dense combination of CDDP/paclitaxel (i.e., condensing the intervals between treatments) in a murine model of CDDP-resistant ovarian cancer (15). The investigators found that this dosing regimen yielded greater intratumoral F4/80+ macrophage and CD8+ T-lymphocyte recruitment than did a standard dosing regimen; they concluded that this improved effector recruitment was responsible for enhanced antitumor efficacy (15). Nevertheless, traditional dosing regimens still appear to yield analogous results, even if to a lesser extent. For example, HPV-16 E7-expressing TC-1 tumor-bearing mice treated with two 10 μg/kg CDDP doses had greater numbers of spleen-infiltrating E7-specific CD8+ T cells than did untreated animals (11).

Notably, such CDDP-mediated recruitment has also been observed when CDDP is combined with adoptive immunotherapy. For example, Chen and colleagues examined the use of CDDP as a preconditioning agent for murine B16 melanoma xenografts treated with intravenously administered cytokine-induced killer (CIK) cells (16). CIK cells are CD3⁺CD56⁺, non–MHC-restricted, natural killer-like T lymphocytes (17). Cisplatin pretreatment augmented the homing ability of CIK cells into tumors, tumor-draining lymph nodes (TLDN), and spleen tissues (16). Moreover, endogenous effector cells, CD3⁺ T lymphocytes, also had increased intratumoral accumulation after CDDP pretreatment (16). These researchers also demonstrated enhanced intratumoral CD3⁺ T-cell accumulation with CDDP treatment and with combined CDDP/adoptive CIK therapy (as compared with controls) in a murine model of colorectal cancer (18). A combination of platinum doublet therapy (CDDP plus vinorelbine) with a recombinant yeast-CEA
consequence of CDDP treatment on CD14
model, Hu and colleagues examined the functional
vitro proliferative effects via more circuitous paths. Using an
in recruiting adoptively transferred chimeric antigen recep-
demonstrate concordant beneficial effects: CDDP also aids
other adoptively transferred cells. In fact, our own data
immune effectors as well as to improve the recruitment of
powerfully, in concert with various novel immunotherapies
necessitate further investigation.

upregulation of PDL-1 (the corresponding ligand to PD-1)
(22). Qin and colleagues showed that CDDP leads to the
cancer (22). Interestingly, these beneficial effects were not
enhanced antitumor efficacy in a murine model of ovarian
treatment with PD-1 checkpoint blockade and CD137 (a T-cell
checkpoint blockade. Specifically, CDDP used in conjunc-
tion with CTLA-4 blockade, an example of the synergistic potential of
CDDP (21). CDDP has also been combined with PD-1
checkpoint blockade. Specifically, CDDP used in conjunc-
tion with PD-1 checkpoint blockade and CD137 (a T-cell
costimulatory molecule) agonist antibody resulted in
enhanced antitumor efficacy in a murine model of ovarian
cancer (22). Interestingly, these beneficial effects were not
seen when PD-1 blockade was excluded from the regimen
(22). Qin and colleagues showed that CDDP leads to the
upregulation of PDL-1 (the corresponding ligand to PD-1)
in tumor cells; an effect also noted with the use of other
chemotherapeutic agents (23, 24). The role of CDDP on
PDL-1 and its combined use with PD-1 blockade both
necessitate further investigation.

Cisplatin-mediated T-cell infiltration has also been stud-
ied in the setting of check-point blockade. For instance, Wu
and colleagues investigated the antitumor and immuno-
modulatory effects of CDDP and combined CDDP/CTLA-4
blockade in a murine mesothelioma model (21). When quantifying relative numbers of tumor-infiltrating CD3\(^+\) T
cells, the authors found that mice treated with CDDP had
significantly increased intratumoral T-cell infiltration than
did untreated controls (21). Moreover, they noted that this
effect became even greater when CDDP was combined with
CTLA-4 blockade, an example of the synergistic potential of
CDDP (21). CDDP has also been combined with PD-1
checkpoint blockade. Specifically, CDDP used in conjunc-
tion with PD-1 checkpoint blockade and CD137 (a T-cell
costimulatory molecule) agonist antibody resulted in
enhanced antitumor efficacy in a murine model of ovarian
cancer (22). Interestingly, these beneficial effects were not
seen when PD-1 blockade was excluded from the regimen
(22). Qin and colleagues showed that CDDP leads to the
upregulation of PDL-1 (the corresponding ligand to PD-1)
in tumor cells; an effect also noted with the use of other
chemotherapeutic agents (23, 24). The role of CDDP on
PDL-1 and its combined use with PD-1 blockade both
necessitate further investigation.

Cisplatin can therefore act either alone or, perhaps more
powerfully, in concert with various novel immunotherapies
to induce the upregulation of numerous endogenous
immune effectors as well as to improve the recruitment of
other adoptively transferred cells. In fact, our own data
demonstrate concordant beneficial effects: CDDP also aids
in recruiting adoptively transferred chimeric antigen recep-
tor-transduced T cells. Interestingly, there is some evidence
that suggests that CDDP may exert some of these recruiting/
proliferative effects via more circuitous paths. Using an in
vitro model, Hu and colleagues examined the functional
consequence of CDDP treatment on CD14\(^+\) monocytes
(rather than the effect of the drug on tumor or effector cells
directly) and the subsequent capacity of these cells to activate CD4\(^+\) T lymphocytes (25). Cisplatin treatment led
to an increased monocyte-induced CD4\(^+\) proliferation and the
effect was largely mediated by the increased production of
IFN\(\gamma\) (25). As a corollary, other studies showed that
CDDP-treated mice bearing TC-1 tumors had considerably
higher percentages of intratumoral CD11c\(^+\) dendritic cells
(which, like monocytes, also serve as APCs) than did
untreated tumor-bearing mice (26).

Therefore, CDDP may not only improve the recruitment
and proliferation of immune effectors such as T cells and
adoptively transferred CIKs, but it may also upregulate the
accumulation of certain APCs as well, APCs that, as we
learned in the previous section, have already had their MHC
class I expression modulated by their exposure to CDDP. It
is tempting to speculate that these now-proliferating MHC
class I-upregulated APCs may then go on to induce addi-
tional T-cell activation and accumulation.

**CDDP upregulates the lytic activity of cytotoxic effectors**

After successfully homing to the tumor microenviron-
ment, cytotoxic effector cells then undertake their cytolytic
functions. CTL-mediated killing typically occurs via the
release of perforin and granzymes from the CTL and/or
through the interaction between Fas (expressed on target
cells) and FasL (a CTL cell-surface protein). Both the
perforin/granzyme and Fas/FasL mechanisms involve activa-
tion of the caspase cascade and ultimately induce tumor-cell
apoptosis. The immunomodulatory effects of CDDP have
also been shown to extend into this aspect of tumor immu-
nology (Fig. 1).

Markasz and colleagues undertook an expansive study of
29 frequently used chemotherapeutic agents and found
that CDDP in vitro at concentrations comparable with
the maximally achieved therapeutic concentrations seen in
clinical practice resulted in enhanced CTL-mediated killing
of lymphoblastoid cell lines, as measured by a standard
51Cr release assay (27). Similar in vitro observations were made in
colorectal cancer (28). Pretreating a primary colon adeno-
carcinoma cell line, SW480, with CDDP increased both
ICAM-1 and Fas expression, resulting in enhanced antigen-
specific CTL (i.e., ras oncogene-specific CD8\(^+\)) mediated
tumor lysis (28). This improved lytic activity with CDDP
was found to involve both Fas-dependent and -independent
mechanisms and was accompanied by an increase in cas-
pase-3–like protease activity (28).

In their in vitro study of platinum doublet therapy in five
human lung carcinoma cell lines (discussed earlier), Gameiro
and colleagues found that sublethal exposure of cancer cells to CDDP/vinorelbine increased their sensitivity to
perforin/granzyme-mediated CTL killing (8). This group
made similar observations when CDDP/vinorelbine was
used in combination with a recombinant yeast-CEA vaccine
in a murine lung tumor model (19). HNSCC cells exposed
to a sublethal combination of CDDP/5-FU were also more
susceptible to antigen-specific MHC-restricted cytotoxic T-
cell killing (9). A recent study examining the use of CDDP
in combination with the chemosensitizing vitamin B6
precursor, pyridoxine, demonstrated that the synergistic
cytotoxicity observed in vitro against non–small cell lung cancer (NSCLC) can translate into improved antitumor efficacy in vivo (29). When given to immunocompetent mice bearing NSCLC tumors, the CDDP/pyridoxine regimen resulted in a 45% cure rate; when given to athymic tumor-bearing mice, this combination CDDP treatment failed to avoid tumor growth and to prolong overall survival, thereby implying that the observed therapeutic effects relied on the presence of thymic-derived T lymphocytes (29).

At the mechanistic level, it appears that CDDP and pyridoxine do not only mediate a synergistic cytotoxic effect, but that they also cooperate in the induction of immunogenic cell death hallmarks. CDDP plus pyridoxine induced more endoplasmic reticulum (ER) stress protein Calreticulin exposure, HMGB1 exodus, and ATP release than did either of the two agents alone. With regard to Calreticulin exposure, both agents interacted synergistically to elicit ER stress at the level of the phosphorylation of eIF2α, which constitutes a stringent requirement for Calreticulin to be exposed. Indeed, CDDP and pyridoxine induced a higher level of eIF2α phosphorylation, if combined rather than used separately.

Considerable evidence therefore exists supporting the notion that CDDP increases a tumor cell’s sensitivity to antigen-specific CTL attack. One possible explanation for this repeatedly observed phenomenon was explored by Ramakrishnan and colleagues, who reported that pretreated tumor cells were sensitized to CTL-mediated lysis in particular due to the cancer cells’ increased permeability to granzyme B after CDDP exposure (30). Of note, this increased permeability allowed antigen-specific CTLs to kill not only antigen-expressing tumor cells, but also neighboring tumor cells not expressing the tumor antigen (30). In addition, the authors demonstrated that this effect was perforin independent and mediated via the upregulation of mannose-6-phosphate receptors on the tumor cells (30).

Therefore, cisplatin exerts its antitumor immunomodulation on effector cells via several mechanisms: it can improve the lytic activity of endogenous CTLs, induce antigen-independent tumor bystander kill, and can even promote the lytic efficacy of adoptively transferred CIKs.

**CDDP downregulates the immunosuppressive microenvironment**

The immunologic microenvironment of a tumor is composed of elements from two competing forces, those that promote tumor eradication (“proimmune” factors like CTLs) and those that promote tumor progression [e.g., immunosuppressive regulatory T cells (Tregs) and other suppressor cells]. The studies outlined thus far illustrated how CDDP can promote various proimmune elements to tip this balance in favor of tumor eradication. However, cancer kill can also be promoted by downregulating the immunosuppressive components of the tumor microenvironment (Fig. 1).

Multiple groups have shown that CDDP can perform such downregulation. For example, as described above, Tseng and colleagues treated TC-1 tumor-bearing mice with CDDP, and showed that treatment with CDDP significantly reduced the levels of myeloid-derived suppressor cells (MDSC) and Tregs in tumor-bearing mice (11). Cisplatin also favorably modulates the immunosuppressive milieu when used in the setting of combination chemotherapy. In their study of the immunomodulatory effects of dose-dense CDDP/paclitaxel (discussed earlier), Chang and colleagues showed that this combined therapy significantly reduced the number of MDSCs as well as the number of Treg cells found in tumor-bearing mice (15). Gameiro and colleagues demonstrated that a single intraperitoneal dose of CDDP/vinorelbine induced a transient modulation of Treg function and markedly reduced the absolute number of Tregs available for immune suppression (19).

A number of researchers studying immunotherapies that are used in conjunction with CDDP have drawn similar conclusions. Chen and colleagues used CDDP as a preconditioning agent in their study on adoptive CIK cell therapy (mentioned earlier) and observed a significant depletion of MDSCs in the TDLNs of CDDP-preconditioned mice (16). Parallel observations were made in a related study in which the ratio of intratumoral FoxP3+ Tregs to CD3+ lymphocytes was significantly reduced with CDDP treatment alone and when CDDP was combined with adoptive CIK therapy (18). Fridlender and colleagues saw similar reductions in Treg numbers in the spleens of mice treated with boost CDDP after initial adenaloviral immunogene therapy (20).

It is intriguing that CDDP dually promotes the function and quantity of effector immune cells while simultaneously counteracting numerous immunosuppressive forces; the detailed mechanisms of these effects are still being investigated. Nevertheless, armed with the preclinical observations detailed above, we next examined the clinical literature for further evidence demonstrating the antitumor immunomodulatory effects of CDDP.

**Clinical Evidence**

Table 1 provides an overview of the clinical literature that supports CDDP-induced antitumor immunomodulation. Chang and colleagues, in their previously mentioned study on the immunomodulatory effects of dose-dense CDDP/paclitaxel, also examined the use of this regimen in 14 patients with relapsed platinum-resistant ovarian cancer (15). During the course of treatment, the authors serially collected patient serum for IFNγ and IL2 quantification, both of which were used as surrogates for cytotoxic CD8+ T-cell activity (15). Of the 4 patients with disease control, the authors determined that three had serum levels of IFNγ and IL2 associated with cytotoxic CD8+ T-cell activity (15). Increases in serum IL2 concentrations have similarly been observed in responders to CDDP-based therapy in stage III/IV therapy-naïve NSCLC (31). Koufos and colleagues isolated the peripheral blood mononuclear cells of 32 such patients and tested the cells for the production of various immunologic factors before and after treatment; the authors found that responders had significant increases...
in IL2 as compared with nonresponders and that patients who responded to treatment and had significant increases in IL2 production had significantly greater median survival (31).

The antitumor immunomodulatory effects of CDDP with respect to both effector and suppressor cells have also been addressed in the clinical literature. Antonia and colleagues studied 29 patients with extensive-stage small cell lung cancer treated with a p53 cancer vaccine in combination with CDDP-based chemotherapy (32). Here, the authors noted p53-specific T-cell responses in 57.1%; one patient with clinical response; (ii) high rate (61.9%) of objective clinical responses to chemotherapy given immediately after vaccination

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (N)</th>
<th>Target malignancy</th>
<th>Interventions</th>
<th>Immunologic studies</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chang et al. (15)</td>
<td>14</td>
<td>Relapsed platinum-resistant ovarian CA</td>
<td>Dose-dense (DD) vs. maximum-tolerated dose CDDP/paclitaxel regimens</td>
<td>Immune cell subset analysis and cytokine profiles</td>
<td>DD regimen: (i) was less toxic to immune system; (ii) reduced immunosuppressive microenvironment; (iii) triggered macrophage and tumor-specific CD8 T-cell responses</td>
</tr>
<tr>
<td>Koufos et al. (31)</td>
<td>32</td>
<td>Stage III/IV, therapy-naïve NSCLC</td>
<td>CDDP/paclitaxel/ifosfamide</td>
<td>Systemic immune responses (i.e., cytokines)</td>
<td>(i) Treatment responders had significantly greater increases in IL2 than did nonresponders</td>
</tr>
<tr>
<td>Antonia et al. (32)</td>
<td>29</td>
<td>Extensive-stage small cell lung CA</td>
<td>p53 cancer vaccine combined w/ cisplatin-based chemotherapy</td>
<td>Phenotype and function of T cells, DCs, and immature myeloid cells were analyzed and correlated w/Ag-specific immune responses</td>
<td>(i) Ag-specific T-cell responses to vaccine seen in 57.1%; one patient w/ clinical response; (ii) high rate (61.9%) of objective clinical responses to chemotherapy given immediately after vaccination</td>
</tr>
<tr>
<td>Roselli et al. (33)</td>
<td>14</td>
<td>Stage IB-IIIA NSCLC</td>
<td>Adjuvant CDDP/vinorelbine</td>
<td>Number and function of peripheral-blood Tregs</td>
<td>(i) Significant decrease in peripheral Tregs after successive treatment cycles; (ii) treatment significantly increased CD4 Teff:Treg ratio; (iii) marked decrease in immunosuppressive activity of circulating Tregs observed in all patients after treatment</td>
</tr>
<tr>
<td>Tsuchikawa et al. (34)</td>
<td>18</td>
<td>Therapy-naïve esophageal squamous cell carcinoma</td>
<td>Neoadjuvant CDDP/5-FU</td>
<td>HLA class I heavy chain, CD4, CD8, Treg infiltrate</td>
<td>Compared with nonneoadjuvant controls, neoadjuvant patients had: (i) significantly more stromal and intratumoral CD4 T cells; (ii) significantly more stromal CD8 T cells; (iii) HLA class I expression more downregulated in controls than in neoadjuvant patients</td>
</tr>
</tbody>
</table>
patients with NSCLC (stages IB, II, and IIIA; ref. 33). The authors found that the ratio between effector CD4+ T cells and Tregs significantly increased in patients receiving CDDP plus vinorelbine; they further determined that the immunosuppressive activity of the Tregs was reduced in the majority of these patients (33). Similar observations were made in a study of 18 therapy-naive squamous cell esophageal carcinoma patients (34). Specifically, patients who received neoadjuvant CDDP/5-FU had significantly higher numbers of stromal and intratumoral CD4+ T cells than did the patients not receiving neoadjuvant treatment (34). In addition, the authors found that the number of stromal CD8+ T cells was also significantly higher in the neoadjuvant group (34).

The aforementioned clinical findings were made in the "real-world" arena of clinical trials (as opposed to a highly controllable preclinical setting) and lend credibility to the monitoring of serum cytokines and/or the quantification of infiltrating or circulating immune cells in gauging the immune responses (both positive and negative) to CDDP.

Conclusions

Increasing preclinical and clinical evidence supports the belief that the anticancer activity of CDDP is not simply due to its ability to cross-link DNA and cause apoptosis. In fact, CDDP can favorably modulate the immune system, both in isolation and in concert with emerging immunotherapies. We now know that (1) even small, sublethal doses of CDDP can upregulate MHC class I expression on tumor cells and APCs; (2) CDDP exposure may improve the recruitment and proliferation of immune effectors such as T cells and adoptively transferred CIKs, as well as certain APCs; (3) CDDP can augment the lytic activity of endogenous and adoptively transferred effector cells and can even induce antigen-independent bystander kill; and (4) CDDP can favorably downregulate immunosuppressive players in the tumor microenvironment, both by itself and synergistically with new immunotherapies. Furthermore, we are now witnessing how CDDP's antitumor immunomodulatory effects are being harnessed clinically, adding new levels of sophistication to disease monitoring and prognostication. The observations summarized above thus lay the foundation for further investigations that might take advantage of CDDP's potential synergism with novel immunotherapies like checkpoint blockade and adoptive T-cell therapy. In addition to exploring the specific pathways of these phenomena in preclinical models, it will be critically important to study the kinetics of CDDP's immunomodulatory influence in patients, as high doses of the drug may negatively impact immune cells. The above-described literature therefore reveals to us additional mechanisms by which CDDP combats tumor, mechanisms that are yet to be exploited in treating solid tumors.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

The laboratory work of P.S. Adusumilli was supported by grants from the NIH (R21 CA164568-01A1, R21 CA164585-01A1, US5 CA137788, P30 CA08789, and P50 CA086438-13), grants from the U.S. Department of Defense (PR101053 and LC110202), the William H. Goodwin and Alice Goodwin and the Commonwealth Foundation for Cancer Research, and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center.

Received July 3, 2014; revised August 21, 2014; accepted August 22, 2014; published OnlineFirst September 9, 2014.
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

Andreas R. de Biasi, Jonathan Villena-Vargas and Prasad S. Adusumilli


Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-14-1298

This article cites 33 articles, 9 of which you can access for free at: http://clincancerres.aacrjournals.org/content/20/21/5384.full.html#ref-list-1

This article has been cited by 3 HighWire-hosted articles. Access the articles at: /content/20/21/5384.full.html#related-urls

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.